Zydus Lifesciences Peer Comparison

NSE: ZYDUSLIFE | BSE: 532321

₹1,123.00

₹-17.20 (-1.51%)

As on 16-Oct-2026IST

Market cap

₹1,12,149 Cr

Revenue (TTM)

₹28,592 Cr

P/E Ratio

24.9

P/B Ratio

4.2

Div. Yield

0.1 %

Edit

	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Mankind Pharma	Lupin
Market cap (₹ Cr)	1,12,149	1,02,820	95,513	93,968	89,437
Revenue (₹ Cr)	28,592	33,228	34,935	14,738	29,967
Net Profit (₹ Cr)	4,492.20	3,169.30	3,712.74	2,055.11	5,551.01
Net Margin (%)	14.92	9.15	10.42	13.64	18.23
RoE (%)	18.78	8.72	10.38	13.60	28.32
Price to Earnings	24.85	31.91	25.73	46.00	16.18
Price-To-Book	4.16	2.69	2.45	5.58	3.76

Income Statement (₹ Cr)

	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Mankind Pharma	Lupin
Operating Revenue	28,591.70	33,227.90	34,935.29	14,737.88	29,966.58
Total Income	30,111.40	34,650.70	35,624.79	15,061.79	30,442.31
Total Expenditure	21,334.70	28,088.10	27,850.01	10,911.05	20,428.27
EBITDA	7,257.00	5,139.80	7,085.28	3,826.83	9,538.31
Depreciation	1,724.60	2,119.30	1,859.31	893.20	1,529.37
EBIT	5,532.40	3,020.50	5,225.97	2,933.63	8,008.94
Interest	510.20	416.30	387.88	578.61	452.37
Other Income	1,519.70	1,422.80	689.50	323.91	475.73
Exceptional Items	-534.80	0.00	-105.51	-129.75	-557.91
Profit before Tax	6,007.10	4,027.00	5,422.08	2,549.18	7,474.39
Provision for Tax	1,514.90	857.70	1,709.34	494.07	1,923.38
Profit after Tax	4,492.20	3,169.30	3,712.74	2,055.11	5,551.01

	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Mankind Pharma	Lupin
Shareholder's Funds	27,111.40	37,891.50	37,890.97	16,300.34	22,448.27
Minority Interest	-79.70	38.90	1.76	-24.90	-22.18
Non-Current Liabilities	7,112.50	3,145.10	2,580.33	5,011.23	3,200.22
Current Liabilities	15,711.90	16,747.40	18,039.01	6,507.25	12,651.24
Total Liabilities	50,672.60	56,576.70	58,196.15	27,754.83	38,146.06

	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Mankind Pharma	Lupin
Non-Current Assets	31,677.20	27,204.00	24,040.45	20,274.65	11,888.82
Current Assets	19,906.10	30,179.30	32,708.75	6,954.20	24,027.38
Total Assets	50,672.60	56,576.70	58,196.15	27,754.83	38,146.06
Total Debt*	11,769.50	7,734.10	7,676.20	6,021.78	5,910.20
Net Current Assets	4,194.20	13,431.90	14,669.74	446.95	11,376.14
Contingent Liabilities	989.90	336.14	1,358.37	924.77	1,094.02

	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Mankind Pharma	Lupin
Cash From Operating Activities	2,116.60	5,673.70	5,526.37	3,121.29	7,334.50
Cash Flow from Investing Activities	-8,296.10	-6,549.30	-3,458.61	-196.42	-3,864.59
Cash from Financing Activities	5,806.90	829.00	-1,269.15	-2,952.69	-845.87
Net Cash Inflow / Outflow	-372.60	-46.60	798.61	-27.82	2,624.04

	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Mankind Pharma	Lupin
ROCE (%)	21.39	13.75	12.76	13.24	28.86
ROE (%)	18.78	8.72	10.38	13.60	28.32
ROA (%)	10.03	5.89	6.86	7.36	16.43
EBIT Margin (%)	19.35	9.09	14.96	19.91	26.73
Net Margin (%)	14.92	9.15	10.42	13.64	18.23
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Mankind Pharma	Lupin
Revenue Growth (%)	21.11	-0.87	9.09	14.16	28.19
EBIT Growth (%)	-8.99	-55.06	6.91	19.45	77.03
Net Profit Growth (%)	-3.14	-44.66	8.63	8.09	49.13
EPS Growth (%)	4.31	-43.29	11.88	12.27	60.86
Book Value Growth (%)	13.19	12.99	16.04	13.74	30.75

	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Mankind Pharma	Lupin
Price / Earnings	22.95	31.91	25.41	43.72	15.00
Price / Book Value	4.16	2.69	2.45	5.58	3.76
Dividend Yield (%)	0.09	0.65	0.24	0.04	0.92
EV/EBITDA	16.08	20.14	13.07	25.60	9.03
Market Cap (₹ Cr)	87,643.18	1,04,763.81	75,689.14	82,801.75	1,05,737.27

	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Mankind Pharma	Lupin
Debt to Equity	0.12	0.00	0.02	0.17	0.07
Short term debt to equity ratio	0.16	0.16	0.16	0.04	0.18
Current Ratio	1.27	1.80	1.81	1.07	1.90
Quick Ratio	0.91	1.35	1.15	0.74	1.42
Interest Coverage	12.77	10.67	14.98	5.41	17.52

	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Mankind Pharma	Lupin
Debtors to sales (%)	18.94	30.47	20.31	11.74	22.04
Asset Turnover	0.64	0.62	0.65	0.53	0.89
Receivable days	33.55	103.79	33.71	39.93	51.23
Inventory Days	33.80	79.94	59.32	51.78	48.93
Payable days	149.82	84.78	148.20	111.46	205.75
Cash Conversion Cycle	-82.46	98.95	-55.17	-19.75	-105.59

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.